AVROBIO Inc. (AVRO) deprioritizing its Fabry disease program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Avrobio Inc. (AVRO) PT Lowered to $6 at Mizuho Securities
January 5, 2022 5:28 PM ESTMizuho Securities analyst Uy Ear lowered the price target on Avrobio Inc. (NASDAQ: AVRO) to $6.00 (from $28.00) while maintaining a Buy rating.
The analyst commented, "The new clinical data from the Fabry program is disappointing. We update our model to exclude our sales and... More
AVROBIO's (AVRO) Focus Shift is Disappointing, But Logical, Outlook is Cautions - Stifel
January 4, 2022 10:37 AM ESTStifel analyst Dae Gon Ha maintains a "Hold" rating on shares of AVROBIO Inc. (NASDAQ: AVRO), following news that company is shifting its portfolio... More
AVROBIO Inc. (AVRO) Halted, News Pending
January 4, 2022 6:55 AM ESTAVROBIO Inc. (NASDAQ: AVRO) Halted, News Pending
